BioLegend, Inc. (BioLegend) acquired the shares of Covance Antibody Services Inc., a business unit of Covance, located in Dedham, Massachusetts, on August 29, 2014.
The Covance Antibody business unit develops and manufactures antibodies and research reagents for Neuroscience, Immunopathology, Cell Biology, Epitope Tags, and Immunohistochemistry Detection.
These products, including In Vitro Diagnostic (IVD) antibodies for IHC, are well-suited to complement and enhance the current selection of BioLegend research reagents.
Covance Antibody customers can expect the same superior customer support and exceptional value with these products as existing BioLegend customers.
"We are excited to add Covance Antibody's people and products to the BioLegend team," said Gene Lay, President, and CEO, BioLegend.
As neuroinflammation and neurodegeneration become increasingly important topics, Covance Antibody is an ideal strategic fit in BioLegend's commitment to the advancement of discovery in neuroscience.
With the addition of a world-class R&D team and over 600 antibody products for emerging and important targets in this field, BioLegend is positioned to become a leader in neuroscience and immunology research.
The addition of Neuroscience and IHC antibody tools to our catalog means accelerated discovery for our current and new customers. We also hope to bring our well-known quality, support, and value in the Immunology community to Neuroscience researchers worldwide."
Gene Lay, President and CEO, BioLegend